No Image Provided

AMLo Biosciences

VC Funding

Series A

Healthcare & Biotech Published 21 April 2022

Summary

In a significant market movement during April 2022, AMLo Biosciences was the subject of a vc funding. The transaction achieved a gross valuation of £2,450,000. Leading the round was Esperante, Northstar Ventures, Ascension’s Life Fund, Future Planet Capital’s BIF Opportunities Fund, Conduit’s EIS Impact Fund.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Esperante

Lead Investor / Acquirer

Northstar Ventures

Lead Investor / Acquirer

Ascension’s Life Fund

Lead Investor / Acquirer

Future Planet Capital’s BIF Opportunities Fund

Lead Investor / Acquirer

Conduit’s EIS Impact Fund

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series A prioritised

VC Funding

Newcells Biotech

£2,350,000

Feb 2024

VC Funding

HutanBio

£2,250,000

Jan 2024

VC Funding

Lottie

£17,253,062

Oct 2023

VC Funding

Skin Analytics

£4,000,000

Sept 2020

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.